Advanced Search

Technical Analysis for CAPR - Capricor Therapeutics, Inc.

Grade Last Price % Change Price Change
grade C 4.8 3.45% 0.16
CAPR closed up 5.94 percent on Friday, May 29, 2020, on 17 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
18 Watchers
Watchlist Portfolio

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down
Historical CAPR trend table...
Date Alert Name Type % Chg
1,2,3 Pullback Bullish Bullish Swing Setup 3.45%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 3.45%
Wide Bands Range Expansion 3.45%
Oversold Stochastic Weakness 3.45%
Wide Bands Range Expansion 9.59%
Down 3 Days in a Row Weakness 9.59%
Oversold Stochastic Weakness 9.59%
Wide Bands Range Expansion 1.16%
Oversold Stochastic Weakness 1.16%
Wide Bands Range Expansion -8.75%
Older EOD signals for CAPR ...
View Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Track My Stocks
Configure default chart indicators
CAPR Chart by TradingView
Basic chart:

Profile

Capricor Therapeutics, Inc., a biotechnology company, is focused on the development of novel therapeutics to prevent and treat cardiovascular diseases. Its lead product candidates include CAP-1002 and Cenderitide. The company was founded in 2005 and is based in Beverly Hills, California.
Biotechnology Life Sciences Cardiovascular Diseases Regulus Therapeutics Two River

Is CAPR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

Recent News

Date Title
May 29 Here is What Hedge Funds Think About Capricor Therapeutics, Inc. (CAPR)
May 26 Capricor to Participate in Maxim Group's COVID-19 Virtual Conference Series on May 27, 2020
May 18 Capricor Therapeutics Inc. (CAPR) CEO Linda Marban on Q1 2020 Results - Earnings Call Transcript
May 18 Capricor Therapeutics, Inc. 2020 Q1 - Results - Earnings Call Presentation
May 14 Capricor Therapeutics (CAPR) Reports Q1 Loss, Lags Revenue Estimates
May 14 Capricor Therapeutics EPS beats by $0.07, misses on revenue
May 14 Capricor Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 13 Capricor Therapeutics to Present First Quarter 2020 Financial Results and Recent Corporate Update on May 14
May 13 Capricor reports positive data from mid-stage study of CAP-1002 in DMD
May 13 Capricor Announces Positive Top-Line Final Results from HOPE-2 Study in Patients with Duchenne Muscular Dystrophy Treated with Lead Candidate CAP-1002
See more CAPR news...

Indicators

Indicator Value
52 Week High 11.08
52 Week Low 0.88
Average Volume 7,576,582
200-Day Moving Average 2.40
50-Day Moving Average 3.65
20-Day Moving Average 6.16
10-Day Moving Average 5.16
Average True Range 0.85
ADX 40.83
+DI 27.19
-DI 24.53
Chandelier Exit (Long, 3 ATRs ) 8.52
Chandelier Exit (Short, 3 ATRs ) 6.28
Upper Bollinger Band 8.38
Lower Bollinger Band 3.94
Percent B (%b) 0.16
BandWidth 71.93
MACD Line 0.21
MACD Signal Line 0.60
MACD Histogram -0.3908
Fundamentals Value
Market Cap 109.02 Million
Num Shares 23.5 Million
EPS -0.82
Price-to-Earnings (P/E) Ratio -5.66
Price-to-Sales 15.44
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.50
Resistance 3 (R3) 5.42 5.06 5.35
Resistance 2 (R2) 5.06 4.84 5.10 5.30
Resistance 1 (R1) 4.85 4.71 4.96 4.93 5.26
Pivot Point 4.49 4.49 4.54 4.53 4.49
Support 1 (S1) 4.28 4.27 4.39 4.36 4.02
Support 2 (S2) 3.92 4.14 3.96 3.98
Support 3 (S3) 3.71 3.92 3.93
Support 4 (S4) 3.79